BMY

Bristol Myers Squibb Company (NYSE: BMY) is a leading global biopharmaceutical firm headquartered in Princeton, New Jersey. Founded through the 1989 merger of Bristol-Myers Company and Squibb Corporation, the company focuses on discovering, developing, and delivering innovative medicines that help patients prevail over serious diseases. Bristol Myers Squibb's product portfolio spans several therapeutic areas, including oncology, cardiovascular, immunology, and neuroscience. The company has expanded its capabilities through strategic acquisitions, such as the purchase of Celgene in 2019, and more recently, the acquisitions of Mirati Therapeutics and Karuna Therapeutics in 2024, enhancing its pipeline in oncology and neuroscience, respectively. With a workforce of over 34,000 employees worldwide, Bristol Myers Squibb remains committed to transforming patients' lives through science .MarketWatch+6MarketWatch+6Wikipedia+6Wikipedia+5Bristol Myers Squibb+5Great Place To Work®+5Wikipedia+1Wikipedia+1Great Place To Work®+1Bristol Myers Squibb+1

Regarding its stock performance, Bristol Myers Squibb's shares have experienced fluctuations over the past year. The stock reached a 52-week high of $63.33 on March 11, 2025, and a 52-week low of $39.35 .MarketWatch+5MarketWatch+5MarketWatch+5MarketWatch+12Reuters+12SoFi+12

In terms of analyst sentiment, as of the latest data, the consensus rating for BMY is "Hold." This consensus is based on 22 Wall Street analysts' evaluations, comprising 2 strong buy ratings, 5 buy ratings, 13 hold ratings, and 2 sell ratings .Value InvestingMarketBeat

Subscribe to our API. See Strong Buy and Sell Signals the Day after They Occur!